Skip to Content
COVID-19 Resources
Cancer Imaging Program (CIP)
Contact CIP
Show menu
Search this site
Last Updated: 10/28/16

Past Other NCI & NIH Initiatives

This page lists past other NCI and NIH cancer imaging initiatives, including grant mechanisms.

Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.

PAR-13-137: Bioengineering Research Grants (R01)

  • Release Date: June 20, 2013
  • Application Receipt Date: Standard dates apply: see http://grants.nih.gov/grants/funding/submissionschedule.htm
  • Expiration Date: Standard dates apply: see http://grants.nih.gov/grants/funding/submissionschedule.htm

PA-12-284: Exploratory / Developmental Bioengineering Research Grants (R21)

  • Release Date: June 20, 2013
  • Application Receipt Date: Standard dates apply: see http://grants.nih.gov/grants/funding/submissionschedule.htm
  • Expiration Date: Standard dates apply: see http://grants.nih.gov/grants/funding/submissionschedule.htm

PAR-13-189: Imaging and Biomarkers for Early Cancer Detection (R01)

  • Release Date: May 14, 2013
  • Application Receipt Date: July 10, 2013, December 11, 2013, July 10, 2014, December 11, 2014, July 10, 2015, December 11, 2015
  • Expiration Date: December 12, 2015
  • Contacts:
    Richard Mazurchuk, Ph.D.
    Phone: 240-276-7126
    Email: mazurchukrv@mail.nih.gov

    Imaging related: Keyvan Farahani, Ph.D.
    Phone: 240-276-5921
    Email: farahank@mail.nih.gov

This Funding Opportunity Announcement (FOA) invites research project (R01) applications that combine imaging and biomarkers. The overall objective of this FOA is to facilitate collaborative imaging and biomarker research to improve cancer screening, early cancer detection and diagnosis by integrating multi modality imaging strategies and multiplexed biomarker methodologies.

PAR-13-174: Revision Applications to P50 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (P50)

  • Release Date: May 14, 2013
  • Application Receipt Date: July 10, 2013
  • Expiration Date: July 11, 2013
  • Contacts:
    Richard Mazurchuk, Ph.D.
    Phone: 240-276-7126
    Email: mazurchukrv@mail.nih.gov

    Imaging related: Keyvan Farahani, Ph.D.
    Phone: 240-276-5921
    Email: farahank@mail.nih.gov

This Funding Opportunity Announcement (FOA) invites revision applications from currently funded SPORE or ICMIC Specialized Centers using the NCI P50 grant mechanism. Revision applications are expected to focus on combined imaging and biomarker approaches to improve screening, early cancer detection and diagnosis by integrating multi modality imaging strategies and multiplexed biomarker methodologies. Depending on the context and focus of the parent P50 award, studies proposed in the revision application must correspond to an additional project expanding the scope of the parent Program Project while maintaining relevance to the overall focus of the parent grant.

PAR-13-175: Revision Applications to P01 Awards for Research on Imaging and biomarkers for Early Cancer Detection (P01)

  • Release Date: May 14, 2013
  • Application Receipt Date: July 10, 2013
  • Expiration Date: July 11, 2013
  • Contacts:
    Richard Mazurchuk, Ph.D.
    Phone: 240-276-7126
    Email: mazurchukrv@mail.nih.gov

    Imaging related: Keyvan Farahani, Ph.D.
    Phone: 240-276-5921
    Email: farahank@mail.nih.gov

This Funding Opportunity Announcement (FOA) invites revision applications from currently funded NIH P01 program projects. Revision applications are expected to focus on combined imaging and biomarker approaches to improve screening, early cancer detection and diagnosis by integrating multi modality imaging strategies and multiplexed biomarker methodologies. Depending on the context and focus of the parent P01 award, studies proposed in the revision application must correspond to an additional project expanding the scope of the parent Program Project while maintaining relevance to the overall focus of the parent grant.

PAR-13-176: Revision Applications to U01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (U01)

  • Release Date: May 14, 2013
  • Application Receipt Date: July 10, 2013; December 11, 2013; July 10, 2014; December 11, 2014; July 10, 2015; December 11, 2015,
  • Expiration Date: December 12, 2015
  • Contacts:
    Richard Mazurchuk, Ph.D.
    Phone: 240-276-7126
    Email: mazurchukrv@mail.nih.gov

    Imaging related: Keyvan Farahani, Ph.D.
    Phone: 240-276-5921
    Email: farahank@mail.nih.gov

This Funding Opportunity Announcement (FOA) invites cooperative agreement research (U01) revision applications from investigators with active NIH U01 research project awards. Revision applications are expected to focus on combined imaging and biomarker approaches to improve screening, early cancer detection and diagnosis by integrating multi modality imaging strategies and multiplexed biomarker methodologies. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded parent U01 Cooperative Agreements.

PAR-13-177: Revision Applications to R01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (R01)

  • Release Date: May 14, 2013
  • Application Receipt Date: July 10, 2013, December 11, 2013, July 10, 2014, December 11, 2014, July 10, 2015, December 11, 2015
  • Expiration Date: December 12, 2015
  • Contacts:
    Richard Mazurchuk, Ph.D.
    Phone: 240-276-7126
    Email: mazurchukrv@mail.nih.gov

    Imaging related: Keyvan Farahani, Ph.D.
    Phone: 240-276-5921
    Email: farahank@mail.nih.gov

This Funding Opportunity Announcement (FOA) invites research project grant (R01) revision applications from investigators with active NIH R01 research project grant awards to support an expansion of the scope of funded R01 project grant awards through the addition of one or more new specific aims. Revision applications are expected to focus oncombined imaging and biomarker approaches to improve screening, early cancer detection and diagnosis by integrating multi modality imaging strategies and multiplexed biomarker methodologies.

Revisions for Early-Stage Development of Informatics Technology (P01)

  • Release Date: September 20, 2012
  • Application Receipt Date: January 22, 2013, June 18, 2013, November 18, 2013, June 18, 2014, November 18, 2014, June 18, 2015.
  • Expiration Date: June 19, 2015
  • Contacts:
    Jiayin (Jerry) Li, M.D., Ph.D.
    Phone: 240-276-6210
    Email: jerry.li@nih.gov

    For contact information for specific areas, please consult the FOA for the complete list.

The purpose of this Funding Opportunity Announcement (FOA) is to invite revisions (formerly called "competing revisions") from currently funded NCI P01 program projects for early-stage development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge. As a component of the NCI’s Informatics Technology for Cancer Research (ITCR) Initiative, this FOA aims to promote interdisciplinary collaboration in the development of innovative computational methods and informatics approaches that are essential for cancer research on all fronts to accelerate scientific discovery and ultimately translate data into knowledge and clinical practice. Applications that focus on data processing and analysis or mathematical/statistical modeling alone without new technology development are not appropriate for this FOA.

Advanced Development of Informatics Technology (U24)

  • Release Date: September 20, 2012
  • Application Receipt Date: January 22, 2013, June 18, 2013, November 18, 2013, June 18, 2014, November 18, 2014, June 18, 2015
  • Expiration Date: June 19, 2015
  • Contacts:
    Jiayin (Jerry) Li, M.D., Ph.D.
    Phone: 240-276-6210
    Email: jerry.li@nih.gov

    For contact information for specific areas, please consult the FOA for the complete list.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge in cancer research. An emerging informatics technology is defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. If successful, these technologies would accelerate research in cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. This FOA is one component of the NCI’s Informatics Technology for Cancer Research (ITCR) Initiative whose central mission is to promote research-driven informatics technology development. Potential applicants who are interested in early-stage development should consult companion FOAs listed on the previous page. Applications that focus on informatics data processing and analysis or mathematical/statistical modeling alone without informatics technology development are not appropriate for this FOA.

Early-Stage Development of Informatics Technology (U01)

  • Release Date: September 20, 2012
  • Application Receipt Date: January 22, 2013, June 18, 2013, November 18, 2013, June 18, 2014, November 18, 2014, June 18, 2015 , by 5:00 PM local time of applicant organization.
  • Expiration Date: June 19, 2015
  • Contacts:
    Jiayin (Jerry) Li, M.D., Ph.D.
    Phone: 240-276-6210
    Email: jerry.li@nih.gov

    For contact information for specific areas, please consult the FOA for the complete list.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge in cancer research. As a component of the NCI’s Informatics Technology for Cancer Research (ITCR) Initiative, this FOA focuses on early-stage development from prototyping to hardening and adaptation. The central mission of the ITCR is to promote research-driven informatics technology development. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research community. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process should be included. Applications that focus on data processing and analysis or mathematical/statistical modeling alone without new technology development are not appropriate for this FOA.

Earliest submission date: December 22, 2012

Revisions for Early-Stage Development of Informatics Technology (U01)

  • Release Date: September 20, 2012
  • Application Receipt Date: January 22, 2013, June 18, 2013, November 18, 2013, June 18, 2014, November 18, 2014, June 18, 2015, by 5:00 PM local time of applicant organization.
  • Expiration Date: June 19, 2015
  • Contacts:
    Jiayin (Jerry) Li, M.D., Ph.D.
    Phone: 240-276-6210
    Email: jerry.li@nih.gov

    For contact information for specific areas, please consult the FOA for the complete list.

The purpose of this Funding Opportunity Announcement (FOA) is to invite revisions (formerly called "competing revisions") from currently funded NCI U01 cooperative agreement projects for early-stage development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge. As a component of the NCI’s Informatics Technology for Cancer Research (ITCR) Initiative, this FOA aims to promote interdisciplinary collaboration in the development of innovative computational methods and informatics approaches that are essential for cancer research on all fronts to accelerate scientific discovery and ultimately translate data into knowledge and clinical practice. Applications that focus on data processing and analysis or mathematical/statistical modeling alone without new technology development are not appropriate for this FOA.

Earliest submission date: December 22, 2012

Revisions for Early-Stage Development of Informatics Technology (R01)

  • Release Date: September 20, 2012
  • Application Receipt Date: January 22, 2013, June 18, 2013, November 18, 2013, June 18, 2014, November 18, 2014, June 18, 2015, by 5:00 PM local time of applicant organization.
  • Expiration Date: June 19, 2015
  • Contacts:
    Jiayin (Jerry) Li, M.D., Ph.D.
    Phone: 240-276-6210
    Email: jerry.li@nih.gov

    For contact information for specific areas, please consult the FOA for the complete list.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 and R37 (MERIT) research projects for early-stage development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge. As a component of the NCI’s Informatics Technology for Cancer Research (ITCR) Initiative, this FOA aims to promote interdisciplinary collaboration in the development of innovative computational methods and informatics approaches that are essential for cancer research on all fronts to accelerate scientific discovery and ultimately translate data into knowledge and clinical practice. Applications that focus on data processing and analysis or mathematical/statistical modeling alone without new technology development are not appropriate for this FOA.

Earliest submission date: December 22, 2012

PAR-12-145: NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21)

  • Release Date: March 29, 2012
  • Application Receipt Date: Earliest submission date May 16, 2012.
  • Expiration Date: September 8, 2015
  • Contacts:

    For this FOA, please see http://www.cancer.gov/researchandfunding/contacts for Scientific/Research Contacts at NCI.

Purpose: The National Cancer Institute (NCI) Exploratory/Developmental Grant (R21) funding opportunity supports the development of new research activities in all areas of cancer research. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (biomedical, behavioral, or clinical).

DE-FOA-0000646: Integrated Nuclear Medicine Research and Training Projects of Excellence

  • Release Date: January 20, 2012
  • Application Receipt Date: Pre-Application (Required) Due Date: February 23, 2012
    Application Due Date: March 28, 2012
  • Expiration Date: March 28, 2012
  • Contacts:
    Dr. Prem Srivastava
    Office of Biological and Environmental Research
    Tel. 301-903-4071
    prem.srivastava@science.doe.gov

This Funding Opportunity aims to serve three important goals:

  1. Research and development of new and highly innovative radiotracer methods and radiotracers as potential imaging agents for nuclear medicine research and application to advance the understanding of normal human physiology and gene expression, diagnosis and management of disease, in drug research and development, and in translational science;
  2. Integrated involvement of postdoctoral fellows (Ph.D. radiochemists) and M.D., or M.D.-Ph.D fellows with specialties in Nuclear Medicine with applications to human health in developing and deploying new radiotracers for nuclear medicine imaging and potential clinical use in humans for disease-specific application;
  3. Enhancement of training opportunities to ensure the future availability of human resources for highly specialized fields of radiotracer development chemistry and clinical nuclear medicine research and allied disciplines.

Pre-Application is Required. Pre-Application Due Date February 23, 2012

CONTINUED DEVELOPMENT AND MAINTENANCE OF SOFTWARE (R01) (MULTIPLE IC'S) (PAR-11-028)

  • Release Date: November 12, 2010
  • Application Receipt Date: Standard dates apply
  • Expiration Date: January 8, 2014
  • Contacts:
    Jerry Li, Ph.D.
    Tel. 240-276-6210
    E-mail: jiayinli@mail.nih.gov
  • Letter of Intent Receipt Date: Not applicable

This Funding Opportunity Announcement is aimed at satisfying one of the needs created by the parallel achievements and increased interdependence of the biological and computing sciences. This interdependence offers an unprecedented opportunity for sophisticated approaches to computer-enabled research in the biological, clinical, and behavioral sciences. The purpose of this program announcement is to assure the availability and continued usefulness of existing biomedical informatics/computational biology software. This program announcement is meant for existing software that serves a biological, clinical, or behavioral community of users. Applications under this program announcement can seek support to improve the existing software in several different ways listed below. Any of these improvements should benefit the existing user community and/or have high potential for attracting significantly more users.

See full description in NIH Guide: PAR-11-028.

PAR-10-234: Bioengineering Research Partnerships (BRP) [R01] (Multiple ICs)

  • Release Date: July 27, 2010
  • Application Receipt Date: Standard dates
  • Expiration Date: September 8, 2013
  • Contacts:
    Albert Lee, Ph.D., NIBIB
    Phone: 301-451-4781
    Email: alee@mail.nih.gov

Participating Institutes and Centers (ICs) of the NIH invite applications for R01 awards to support Bioengineering Research Partnerships (BRPs) for basic, applied, and translational multi-disciplinary research that addresses important biological, clinical, or biomedical research problems. In the context of this program, a partnership is a multi-disciplinary research team that applies an integrative, systems approach to develop knowledge and/or methods to prevent, detect, diagnose, or treat disease or to understand health and behavior.

See full description in NIH Guide: PAR-10-234

DEVELOPMENT OF ASSAYS FOR HIGH-THROUGHPUT DRUG SCREENING (NIDDK, NCI, NIAID, NIMH) (R01) (PA-10-213)

  • Release Date: June 10, 2010
  • Application Receipt Date: Standard Dates
  • Expiration Date: September 8, 2013
  • Contacts:
    Robert G Lees, Ph.D., NCI
    Phone: 301-496-8783
    Email: leesro@mail.nih.gov

The purpose of this FOA is to stimulate the development of assays for high throughput screening (HTS) relevant to processes and diseases specific to the mission of the institutes involved, with the intent of using the assays to screen for small molecule compounds that show desired properties as probes for use in advancing knowledge about the relevant target, identifying new targets, or serving as pre-therapeutic leads.

NCI:Assays pertinent to the mission of NCI should be justified in the application as relevant to cancer. The NCI is interested in development of assays to identify or evaluate small molecules for use in elucidating molecular, cellular, or in vivo mechanisms or processes of probable or known importance to cancer biology, and for use in developing strategies for cancer prevention, diagnosis, treatment or clinical monitoring of treatment. Assays proposed may be biochemical, cellular or model organism-based, and may be useful for discovering small molecule probes, preventive or therapeutic drug leads, or imaging agent leads. Applicants may find the NCI Developmental Therapeutics Program resources to be helpful. Collaborations between laboratories with screen development capabilities and laboratories with small molecule synthesis capabilities are encouraged.

See full description in NIH Guide: PA-10-213

Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Postdoctoral Fellows (F32) (PA-10-110)

The objective of NIH-supported Ruth L. Kirschstein National Research Service Awards programs is to help ensure that a diverse pool of highly trained scientists are available in adequate numbers and in appropriate research areas to address the Nation’s biomedical, behavioral, and clinical research needs.

The purpose of the postdoctoral fellowship (F32) award is to provide support to promising postdoctoral applicants who have the potential to become productive and successful independent research investigators. The proposed postdoctoral training must offer an opportunity to enhance the applicant’s understanding of the health-related sciences, and must be within the broad scope of biomedical, behavioral, or clinical research or other specific disciplines relevant to the research mission of the participating NIH Institutes and Centers. Applicants with a health professional doctoral degree may use the proposed postdoctoral training to satisfy a portion of the degree requirements for a master’s degree, a research doctoral degree or any other advanced research degree program.

The NRSA legislation requires that the Nation’s overall needs for biomedical research personnel be taken into account by giving special consideration to physicians and other health professionals who propose to become active biomedical researchers and who agree to undertake a minimum of 2 years of biomedical, behavioral or clinical research. Individuals from diverse racial and ethnic groups and individuals with disabilities and individuals from disadvantaged backgrounds are always encouraged to apply for NIH support.

Each NIH Institute and Center (IC) has a unique scientific purview and different program goals and initiatives that evolve over time. Prospective Fellowship Applicants are encouraged to contact the relevant NIH staff for IC-specific programmatic information: Table of Institute and Center Contacts.

URL: http://grants.nih.gov/grants/guide/pa-files/PA-10-110.html

Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Senior Fellows (F33) (PA-10-111)

The National Institutes of Health (NIH) awards individual senior level research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers. The primary objective of this funding opportunity is to help ensure that diverse pools of highly trained scientists will be available in adequate numbers and in appropriate research areas to carry out the Nation’s biomedical, behavioral and clinical research agendas.

URL: http://grants.nih.gov/grants/guide/pa-files/PA-10-111.html

Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellowships (F31) to Promote Diversity in Health-Related Research (PA-10-109)

The Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellowships to Promote Diversity in Health-Related Research will provide up to five years of support for research training leading to the Ph.D. or equivalent research degree, the combined M.D./Ph.D. degree; or another formally combined professional degree and research doctoral degree in biomedical, behavioral, health services, or clinical sciences. These fellowships will enhance the diversity of the biomedical, behavioral, health services, and clinical research labor force in the United States by providing opportunities for academic institutions to identify and recruit students from diverse population groups to seek graduate degrees in health-related research and apply for this fellowship. The overall goal of this program is to increase the number of scientists from diverse population groups who are prepared to pursue careers in biomedical, behavioral, social, clinical, or health services research.

URL: http://grants.nih.gov/grants/guide/pa-files/PA-10-109.html

PA-10-063: NIH Pathway to Independence (PI) Award (K99/R00)

  • Release Date: December 16, 2009
  • Application Receipt Date: standard dates
  • Expiration Date: January 8, 2013
  • Contacts:
    Nancy C. Lohrey, MS, MT-ASCP, NCI
    Phone: 301-496-8580
    Email: LohreyN@mail.nih.gov

The primary purpose of the Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented NIH-supported independent investigators. The program is designed to facilitate a timely transition from a mentored postdoctoral research position to a stable independent research position with independent NIH or other independent research support at an earlier stage than is currently the norm. Prospective candidates are encouraged to contact the relevant NIH staff for IC-specific programmatic and budgetary information.

The K99/R00 program must be tailored to meet the individual needs of the candidate. Candidates may request up to 5 years of support consisting of two phases. The initial phase will provide 1-2 years of mentored support for highly promising, postdoctoral research scientists. This phase will be followed by up to 3 years of independent support contingent on securing an independent tenure-track or equivalent research position. R00 award recipients are expected to apply for additional NIH or other independent research grant support during the independent phase of the award.

Grants awarded by NCI under this announcement will be funded as Howard Temin Pathway to Independence Awards in Cancer Research.

The candidate’s research proposal must be laboratory-based and must include research on the etiology, pathogenesis, prevention, diagnosis, control or treatment of HUMAN cancer. The proposed research may involve model systems, including animal models. However, at some point during the grant period, the proposed research must include work on human cancer (includes human cancer cells or tissues).

Candidates must be able to identify an individual with extensive experience in human cancer research who can serve as a mentor for the initial mentored phase of this award.

See full description in NIH Guide: PA-10-063

PA-10-036: Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32)

The objective of the NRSA program is to provide predoctoral and postdoctoral research training opportunities for individuals interested in pursuing research careers in biomedical, behavioral and clinical research. Each NIH Institute and Center has a unique scientific purview and different program goals and initiatives that evolve over time. It is therefore critical that all applicants consult with the scientific/research contact at the relevant NIH Institute or Center for current information about program priorities and policies before preparing an application. This action is of utmost importance because applications with marginal or no relevance to the NIH awarding components participating in this funding opportunity announcement will not be accepted for review or considered for funding.

See full description in NIH Guide: PA-10-036

PA-10-010: Exploratory/Developmental Bioengineering Research Grants(EBRG) [R21]

  • Release Date: October 14, 2009
  • Application Receipt Date: Standard dates apply
  • Expiration Date: January 8, 2013
  • Contacts:
    Houston Baker, Ph.D., NCI
    Phone: 301-594-9117
    Email: bakerhou@mail.nih.gov

The EBRG can support: 1) innovative, high-risk, high pay-off projects; 2) exploration of new approaches or concepts to a particular substantive area; 3) research and development of new technologies, techniques or methods; or 4) initial research and development of data upon which significant future research may be built. In keeping with the intent of the R21 program, there may or may not be any preliminary results.

Participating institutes are NIBIB, NICHD, NCI, NEI, NHLBI, NHGRI, NIA, NIAAA, NIAMS, NIDCD, NIDCR, NIDA, NIEHS, NIMH, and NINDS.

See full description in NIH Guide: PA-10-010

PA-10-009: Bioengineering Research Grants (BRG)(R01)

  • Release Date: October 14, 2009
  • Application Receipt Date: Standard dates apply
  • Expiration Date: January 8, 2013
  • Contacts:
    Houston Baker, Ph.D., NCI
    Phone: 301-594-9117
    Email: bakerhou@mail.nih.gov

Participating Institutes and Centers invite applications for R01 awards to support Bioengineering Research Grants (BRGs) for basic and applied multi-disciplinary research that addresses important biological, bioengineering or medical research problems. The BRGs support multi-disciplinary research performed in a single laboratory or by a small number of investigators that applies an integrative, systems approach to develop knowledge and/or methods to prevent, detect, diagnose, or treat disease or to understand health and behavior. A BRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research.

Please see the NIH Guide Notice for PA-10-009.

PA-10-009 Bioengineering Research Grants (BRG)(R01)

  • Release Date: October 14, 2009
  • Application Receipt Date: Standard dates apply
  • Expiration Date: January 8, 2013
  • Contacts:
    Houston Baker, Ph.D., NCI
    Phone: 301-594-9117
    Email: bakerhou@mail.nih.gov

Participating Institutes and Centers of the NIH invite applications for R01 awards to support Bioengineering Research Grants (BRGs) for basic and applied multi-disciplinary research that addresses important biological, bioengineering or medical research problems. The BRGs support multi-disciplinary research performed in a single laboratory or by a small number of investigators that applies an integrative, systems approach to develop knowledge and/or methods to prevent, detect, diagnose, or treat disease or to understand health and behavior. A BRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research.

See full description in NIH Guide: PA-10-009

PA-10-010: Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21)

  • Release Date: October 14, 2009
  • Application Receipt Date: Standard dates apply
  • Expiration Date: January 8, 2013
  • Contacts:
    Houston Baker, Ph.D., NCI
    Phone: 301-594-9117
    Email: bakerhou@mail.nih.gov

This Funding Opportunity Announcement (FOA) is intended to encourage innovation and high risk/impact bioengineering research in new areas. While minimal or no preliminary data are expected to be described in the application, applications should clearly indicate the significance of the proposed work and that the proposed research and/or development is scientifically sound, that the qualifications of the investigators are appropriate, and that resources available to the investigators are adequate. An EBRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research.

Participating institutes are NIBIB, NICHD, NCI, NEI, NHLBI, NHGRI, NIA, NIAAA, NIAMS, NIDCD, NIDCR, NIDA, NIEHS, NIMH, and NINDS.

See full description in NIH Guide: PA-10-010

PA-08-243:Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (R01)

  • Release Date: August 19, 2009
  • Application Receipt Date: Standard dates apply
  • Expiration Date: September 8, 2011
  • Contacts:
    Heng Xie, M.D., M.P.H., Ph.D., NCI
    Phone: 301-496-8866
    Email: XieHe@mail.nih.gov

This FOA encourages research activities in the broad areas of etiology and etiologic mechanism(s) of liver cancer, include, but are not limited to: (a) identification of viral and host factors in initiation of HCC, (b) examination of the development of HCC in the sequelae of HIV infection(c) development of animal models and in vitro virus cultivation methods; (d) development of prevention and control strategies, including chemoprevention; (e), validation of markers; (f) preclinical or clinical trials of promising agents; and (g) imaging studies for diagnosis and intervention.

Research topics include research on the treatment and diagnosis of HCC, including Conduct of therapeutic clinical trials designed to evaluate novel anticancer agents with distinctive molecular targets, as well as therapeutic combinations of novel agents; Conduct of clinical translational research on promising biomarkers for determining prognosis and/or predicting response(s) to therapy; Development of functional imaging techniques that can reliably distinguish HCC from benign hepatic lesions; Conduct of clinical trials designed to evaluate the role, efficacy, and safety of image-guided local therapies, such as radio-frequency thermal ablation (RFA), particularly in relation to use of liver transplantation for patients with small HCC; Test of the utility of imaging modalities to evaluate pharmacokinetics and pharmacodynamics of targeted therapies; Evaluation of the use of imaging as a surrogate marker or endpoint for drug activity in therapeutic clinical trials; and Development of novel imaging approaches that can be used as diagnostic tools for early detection of HCC.

URL: http://grants.nih.gov/grants/guide/pa-files/PA-08-243.html

PAR-09-219: Exploratory Innovations in Biomedical Computational Science and Technology (R21)

  • Release Date: August 17, 2009
  • Application Receipt Date: Standard dates
  • Expiration Date: Extended to September 8, 2013 (Original expiration date September 8, 2012)
  • Contacts:
    Peter Lyster, Ph.D., NIGMS
    Phone: 301-451-6446
    Email: lysterp@mail.nih.gov

The NIH is interested in promoting research and developments in computational science and technology that will support rapid progress in areas of scientific opportunity in biomedical research. As defined here, biomedical informatics and computational biology includes database design, graphical interfaces, querying approaches, data retrieval, data visualization and manipulation, data integration through the development of integrated analytical tools, and tools for electronic collaboration, as well as computational and mathematical research including the development of structural, functional, integrative, and analytical computational models and simulations.

See full description in NIH Guide:PAR-09-219

PAR-09-251:Optimization of Small Molecule Probes for the Nervous System (R21)

  • Release Date: August 13, 2009
  • Application Receipt Date: Standard dates apply
  • Expiration Date: September 8, 2012
  • Contacts:
    Mark Scheideler, Ph.D.
    Phone: 301-496-1779
    Email: scheidelerm@ninds.nih.gov

This FOA issued by participating institutes of the National Institutes of Health, encourages research grant applications from institutions/organizations that propose to develop new small molecule probes for investigating biological function in the nervous system via the application of advanced medicinal chemistry and the biological testing of compounds. Eligible investigators will have identified probe candidates via screening of small molecule collections, using in vitro assays of biological activity developed to interrogate these collections, and be able to show that the structural features of these small molecules are related to their biological activity. Proposals should nominate small molecule probe candidates from distinct structural series for the further, iterative design and testing of analogues in structure-activity relationship studies, using in vitro assays of biological function adapted to the medium throughput screening requirements of this work. These studies should have the goal of developing a small molecule probe possessing the attributes (eg: affinity, selectivity, activity) required for its use in future pharmacological studies proposed by the investigator. Applicants are strongly encouraged to utilize publicly available cheminformatic capabilities for the acquisition of compounds, and semi-custom synthesis of analogues.

Proposals should include both a biological and chemical component. The biological component should include a plan of in vitro and, when appropriate, limited in vivo assays, each capable of measuring the activity of a test compound towards an attribute that the "hit" compound proposed as a starting point for modification possesses, and that needs to be further enhanced or eliminated by redesign of the "hit".

See full description in NIH Guide:
R21: PAR-09-251
R41/41 STTR: PAR-09-259
R41/41 SBIR: PAR-09-260

PAR-09-218: Innovations in Biomedical Computational Science and Technology (R01)

  • Release Date: August 05, 2009
  • Application Receipt Date: Standard dates apply
  • Expiration Date: Extended to September 8, 2013 (Original expiration date September 8, 2012)
  • Contacts:
    Peter Lyster, Ph.D., NIGMS
    Phone: 301-451-6446
    Email: lysterp@mail.nih.gov

The NIH is interested in promoting research and developments in biomedical informatics and computational biology that will support rapid progress in areas of scientific opportunity in biomedical research. As defined here, biomedical informatics and computational biology includes database design, graphical interfaces, querying approaches, data retrieval, data visualization and manipulation, data integration through the development of integrated analytical tools, and tools for electronic collaboration, as well as computational and mathematical research including the development of structural, functional, integrative, and analytical computational models and simulations.

See full description in NIH Guide: PAR-09-218

PAR-09-220, 221: Innovations in Biomedical Computational Science and Technology Initiative (SBIR [R43/R44]), (STTR {R41/R42)]

  • Release Date: August 05, 2009
  • Application Receipt Date: Standard dates apply
  • Expiration Date: Extended to September 8, 2013 (Original expiration date September 8, 2012)
  • Contacts:
    Peter Lyster, Ph.D., NIGMS
    Phone: 301-451-6446
    Email: lysterp@mail.nih.gov

This funding opportunity announcement (FOA) solicits Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) that propose innovative research in biomedical informatics and computational biology to promote the progress of biomedical research. There exists an expanding need to speed the progress of biomedical research through the power of computing to manage and analyze data and to model biological processes. The NIH is interested in promoting research and developments in biomedical computational science and technology that will support rapid progress in areas of scientific opportunity in biomedical research. As defined here biomedical computing or biomedical information science and technology includes database design, graphical interfaces, querying approaches, data retrieval, data visualization and manipulation, data integration through the development of integrated analytical tools, and tools for electronic collaboration, as well as computational research including the development of structural, functional, integrative, and analytical computational models and simulations.

URLs:
http://grants.nih.gov/grants/guide/pa-files/PAR-09-220.html (SBIR)
http://grants.nih.gov/grants/guide/pa-files/PAR-09-221.html (STTR)

Non-Invasive Methods for Diagnosis and Progression of Diabetes, Kidney, Urological, Hematological and Digestive Diseases (R01) (NIDDK) (PA-09-181)

  • Release Date: May 01, 2009
  • Application Receipt Date: Standard dates apply
  • Expiration Date: May 8, 2012
  • Contacts:
    Maren R Laughlin, Ph.D., NIDDK
    Phone: 301-594-8802
    Email: ml33g@nih.gov

This Funding Opportunity Announcement (FOA) is a call for the application of imaging and other non- or minimally-invasive technologies to detect, characterize, diagnose, identify persons with predisposition to, or monitor treatment of diseases of interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH). Also needed are new, robust surrogate markers for clinical trial endpoints, and new ways to characterize normal and pathological tissues in vivo. Diseases of interest include type 1 and 2 diabetes; acute and chronic kidney disease, liver, urologic, hematologic, digestive, endocrine, and metabolic diseases and their complications; obesity; obesity-related hypertension, hypertension, renal and vascular disorders leading to hypertension. Applicable techniques include molecular imaging and functional imaging approaches, imaging methods with high spatial, chemical or time resolution, metabolomics, proteomics, genomics, or new spectroscopic or sensor array technologies for monitoring metabolic or physiological events.

URL: http://grants.nih.gov/grants/guide/pa-files/PA-09-181.html

PAR-09-129: Solicitation of assays for high throughput screening (HTS) in the molecular libraries screening centers network (MLPCN)(R03)

  • Release Date: March 12, 2009
  • Application Receipt Date: See below
  • Expiration Date: January 5, 2012
  • Contacts:
    Yong Yao, Ph.D., NIH Roadmap Molecular Libraries and Imaging
    Phone: (301) 443-6102
    Email: yyao@mail.nih.gov
  • Letters of Intent Receipt Date(s): Letters of Intent Receipt Date(s): Apr. 13, 2009; Aug. 4, 2009; Dec. 4. 2009; Apr. 4, 2010; Aug. 3, 2010; Dec. 4, 2010; Apr. 4, 2011; Aug. 2, 2011; and Dec. 4, 2011.
  • Application Submission Date(s): May 13, 2009; Sept. 4, 2009; Jan. 4. 2010; May 4, 2010; Sept. 3, 2010; Jan. 4, 2011; May 4, 2011; Sept. 2, 2011; and Jan. 4, 2012.

The NIH Molecular Libraries Roadmap Initiative wishes to solicit HTS assay applications from investigators who have the interest and capability to work with the Molecular Libraries Probe Production Centers Network (MLPCN) in support of chemical probe development. This FOA promotes discovery and development of new chemical probes as research tools for use by scientists in both the public and private sector to advance the understanding of biological functions and disease mechanisms.

See full description in NIH Guide:PAR-09-129

PAR-09-089: The NCI Transition Career Development Award (K22)

  • Release Date: January 23, 2009
  • Application Receipt Date: Standard dates apply
  • Expiration Date: January 8, 2012
  • Contacts:
    Sonia Jakowlew, Ph.D.
    Phone: 301-496-8580
    Email: jakowles@mail.nih.gov

The major objective of the NCI Transition Career Development Award program is two-fold: (i) to provide a mechanism for stabilizing the career tracks of the most promising of investigators while they are establishing their first independent research programs and (ii) to create equal access to extramural career development opportunities to postdoctoral scientists in basic human cancer research working as Federal employees.

See full description in NIH Guide: PAR-09-089

PAR-09-088: Established Investigator Award in Cancer Prevention & Control (K05)

  • Release Date: January 22, 2009
  • Application Receipt Date: Standard dates apply for K award
  • Expiration Date: January 8, 2012
  • Contacts:
    Shannon M. Lemrow, Ph.D., NCI
    Phone: 301-496-8580
    Email: lemrows@mail.nih.gov

The objective of the NCI Established Investigator Award in Cancer Prevention and Control (K05) is to provide qualified researchers with protected time to devote to research and mentoring. The award is designed for established scientists who have already demonstrated a sustained, high level of research and mentoring productivity and who need K05 support to continue these activities. The K05 award will provide salary support of 25 to 50 percent of the institutional base salary (up to the current Federal salary cap limit) for three to five years based on a full-time, 12-month staff appointment, plus fringe benefits. The award requires the candidate to devote a minimum of 25 percent of full-time professional effort towards conducting the experimental research plan and the mentoring activities described in the application. The award also provides $25,000 per year in research-related expenses. It is renewable for one additional 5-year period.

See full description in NIH Guide: PAR-09-088

PA-09-043: Mentored Patient-Oriented Research Career Development Award (K23)

The goal of the Mentored Patient-Oriented Research Career Development Award (K23) program is to ensure a future cadre of well-trained scientists working in POR areas who will become competitive for NIH research project (R01) grant support. The specific objectives of the Mentored Patient-Oriented Research Career Development Award are to:

1)encourage research-oriented clinicians to develop independent research skills and gain experience in advanced methods and experimental approaches needed to become an independent investigator conducting patient-oriented research; 2) increase the pool of clinical researchers who can conduct patient-oriented studies, capitalizing on the discoveries of biomedical research and translating them to clinical settings; 3) support the career development of investigators who have made a commitment to focus their research endeavors on patient-oriented research.

For the purposes of this award, Patient-Oriented Research is defined as research conducted with human subjects (or on material of human origin such as tissues, specimens and cognitive phenomena) for which an investigator directly interacts with human subjects. This area of research includes: 1) mechanisms of human disease; 2) therapeutic interventions; 3) clinical trials, and; 4) the development of new technologies. Studies falling under Exemption 4 for human subjects research are not included in this definition.

See full description in NIH Guide: PA-09-043

PA-09-042: Mentored Clinical Scientist Research Career Development Award (K08)

  • Release Date: December 11, 2008
  • Application Receipt Date: Multiple dates, see announcement
  • Expiration Date: January 8, 2012
  • Contacts:
    Dorkina Myrick, M.D., Ph.D. (NCI)
    Phone: 301-496-8580
    Email: Myrick@mail.nih.gov

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. Individuals with a clinical doctoral degree interested in pursuing a career in patient-oriented research should refer to the NIH Mentored Patient-Oriented Research Career Development Award (K23).

An award provides support for salary and research-related costs. The amount funded as salary for a career development award varies among the NIH participating Institutes and Centers (ICs). Therefore, the applicant is strongly advised to contact the relevant IC for any distinct guidelines, requirements, and allowable funds (http://grants.nih.gov/grants/guide/contacts/PA-09-042_contacts.html).

See full description in NIH Guide: PAR-09-042

PA-09-004 & PA-09-005: Understanding the effects of emerging cellular, molecular, and genomic technologies on cancer health care delivery (R01) & (R21) (NCI)

  • Release Date: October 06, 2008
  • Application Receipt Date: Standard dates apply
  • Expiration Date: January 8, 2012
  • Contacts:
    Andrew Freedman, Ph.D., NCI
    Phone: 301-435-6819
    Email: freedmaa@mail.nih.gov

The purpose is to invite applications for health services research addressing utilization of emerging cellular, molecular, and genetic or genomic (CMG) technologies in cancer care. The studies will assess CMG technologies in relation to: quality of care; organizational barriers and change factors in utilization; cost and cost-effectiveness; disparities in access and efficacy; monitoring of cross-sectional patterns of care and time trends; impact on existing standards of care, and; influence on cancer outcomes such as incidence, progression, mortality, survival, and quality of life. This funding opportunity specifically encourages research on commercially available CMG clinical tools already in use, as well as experimental tools in the later stages of development and/or in the regulatory approval pipeline.

See full description in NIH Guide: R01 PA-09-004; R21 PA-09-005

PAR-08-120: Cancer Education Grants Program (R25)

  • Release Date: March 28, 2008
  • Application Receipt Date: Standard dates apply
  • Expiration Date: September 8, 2011
  • Contacts:
    Lester Gorelic, Ph.D.
    Tel: (301) 496-8580
    Email: gorelicl@mail.nih.gov

This Funding Opportunity Announcement (FOA) uses the NIH Research Education (R25) grant mechanism to support the following types of programs: innovative educational programs intended to motivate biomedical and other health science students to pursue cancer related careers; short courses to update cancer research scientists in new scientific methods, technologies and findings; training of cancer care clinicians and community health care providers in evidence-based cancer prevention and control approaches; development of effective innovative education (dissemination) approaches to translate knowledge gained from science (discovery) into public health and community applications (delivery).

Because the nature and scope of the proposed research education program will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.

The total project period for an application submitted in response to this funding opportunity may not exceed five years. Direct costs are limited to $300,000 per year.

See full description in NIH Guide: PAR-08-120

PA-08-098: Functional Links between the Immune System, Brain Function and Behavior (R21)

  • Release Date: March 04, 2008
  • Application Receipt Date: Standard dates
  • Expiration Date: May 17, 2011
  • Contacts:
    Paige McDonald, Ph.D., MPH
    Phone: 301-435-5037
    Email: mcdonalp@mail.nih.gov

The potent effects of neuroimmune molecules in the brain are mediated through multiple signaling pathways. However, details regarding the extent, routes, or mechanisms whereby immune signaling affects the brain in either normal conditions or during immune challenge and inflammation are largely unexplored. The purpose of this FOA is to identify research opportunities that may help to bridge the gap in understanding how immune cells and their mediators affect brain development, function and behaviors related to cognition and mood.

See full description in NIH Guide: PA-08-098

Nanoscience and Nanotechnology in Biology and Medicine (R01: PAR-08-052); (R21: PAR-08-053)

  • Release Date: December 18, 2007
  • Application Receipt Date: Standard dates apply
  • Expiration Date: January 8, 2011
  • Contacts:
    Piotr Grodzinski
    grodzinp@mail.nih.gov

This funding opportunity (FOA) is aimed at enhancing nanoscience and nanotechnology research focused on problems in biology and medicine. Nanoscience and nanotechnology refer to research and development on the understanding and control of matter at a length scale of approximately 1 - 100 nanometers, where novel properties and functions occur because of the size. The National Cancer Institute (NCI) is interested in: 1. Early detection of the disease using imaging, 2. In vitro early diagnostics: multiplexed sensitive and specific sensors, 3. Multi-functional therapeutics and localized therapy delivery, and 4. Tools and approaches to interrogate, understand, and manipulate single cells, structures , and molecules.

URLs:
http://grants.nih.gov/grants/guide/pa-files/PAR-08-052.html (R01)
http://grants.nih.gov/grants/guide/pa-files/PAR-08.053.html (R21)

PAR-08-055: Cancer Prevention Research Small Grant Program (R03)

  • Release Date: December 17, 2007
  • Application Receipt Date: See below
  • Expiration Date: December 10, 2010
  • Contacts:
    Lynn Sobara, Ph.D.
    Tel: (301) 435-0584
    Email: LynnS@mail.nih.gov
  • Application Receipt Dates: March 19, July18, December 19, 2008; March 20, July 17, December 18, 2009; March 19, July 19, December 9, 2010

This Funding Opportunity Announcement is designed to enhance the basic and applied cancer prevention research. The National Cancer Institute (NCI) invites applications that propose small and time-limited projects pertinent to the development of cancer chemoprevention agents, biomarkers for early cancer detection, cancer-related nutrition science, and/or clinical prevention studies that focus on specific target organs. Proposed projects may involve basic and/or translational research and/or human subjects-oriented research. Budgets for direct costs of up to $50,000 per year may be requested for a maximum of $100,000 direct costs over a 2-year (maximum time length) project period. Among the Early Cancer Detection topics mentioned in the specific areas of research is imaging technology. The scope of the funding mechanism includes pilot or feasibility studies; secondary analyses of existing data; small, self-contained research projects; development of research methodologies; and development of new research technologies.

See full description in NIH Guide: PAR-08-055

COLLABORATIVE RESEARCH TO EXPLORE NEW USES FOR EXISTING RADIOLIGANDS (NIDA, NIA, NIMH, NINDS) (R21/R33) (RFA-DA-08-001)

  • Release Date: August 08, 2007
  • Application Receipt Date: January 28, 2008
  • Expiration Date: January 29, 2008
  • Contacts:
    Linda Brady, Ph.D.
    Tel 301-443-3563
    E-mail: lbrady@nimh.nih.gov
  • Letters of Intent Receipt Date: December 28, 2007

The purpose of the FOA, issued by the NIDA, NINDS, NIA, and NIMH, is to facilitate collaborations to extend the utility of positron emission tomography (PET) or single photon emission tomography (SPECT) radioligands in the study of brain and other organ systems to diseases beyond those for which the ligand was originally developed. An example might be the use of radioligands synthesized for probing brain systems in substance abuse for the investigation of other diseases such as cancer, schizophrenia, or obesity, or of organs other than the brain, e.g., heart, kidney, adrenal gland, ovary. Similarly, radioligands developed in a patient population afflicted with a specific disease or condition might be applied to other clinical populations with different conditions or diseases. Very often, PET or SPECT radioligands are developed at a single site with a single intended application in mind. This FOA seeks to encourage collaborations between sites that develop and use PET and/or SPECT radioligands for the purpose of expanding the range of ligand applications as well as sharing the ligands themselves or the procedures used in their development/synthesis. The overall goal of this solicitation is to optimize the utility of PET/SPECT radiotracers across organ systems and diseases and between and among sites in human subjects.

See full description in NIH Guide: RFA-DA-08-001

SHARING DATA AND TOOLS: FEDERATION USING THE BIRN AND caBIG INFRASTRUCTURES (MULTIPLE INSTITUTES) (R01) (PAR-07-426)

  • Release Date: August 03, 2007
  • Application Receipt Date: January 18, 2008, September 18, 2008, January 21, 2009, and September 21, 2009
  • Expiration Date: September 22, 2009
  • Contacts:
    Jennifer Couch, Ph.D.
    Tel: (301) 435-5226
    Email: couchj@mail.nih.gov

The NIH Blueprint for Neuroscience Research is a collaborative effort among the NIH Office of the Director and 15 Institutes and Centers to accelerate the pace of discovery and understanding in neuroscience research (for details see the following: http://neuroscienceblueprint.nih.gov/). This FOA is affiliated with the Neuroscience Blueprint, with Institutes and Centers participating independently, and with participation by Institutes that are not part of the Neuroscience Blueprint. The purpose of this FOA is to encourage researchers to use the caBIG™ and BIRN infrastructures to share data and tools by federating new software tools under these infrastructures or using the infrastructure to federate significant data sets. Awards issued under this FOA will NOT provide support to develop the tools or to measure data. The goal is to make these tools/data broadly available to other researchers.

See full description in NIH Guide: PAR-07-426

LYMPHATIC BIOLOGY IN HEALTH AND DISEASE (R01) (NCI, NHLBI, NICHD, NIDDK, NINR) (PAR-07-420)

  • Release Date: July 27, 2007
  • Application Receipt Date: September 28, 2007, September 18, 2008, September 18, 2009
  • Expiration Date: September 19, 2009
  • Contacts:
    Suresh Mohla, Ph.D.
    Phone: 301-435-1878
    E-mail: mohlas@mail.nih.gov
  • Letters of Intent Receipt Date(s): August 27, 2007, August 16, 2008, August 17, 2009

This Funding Opportunity Announcement issued by the National Heart, Lung, and Blood Institute (NHLBI), in conjunction with other Institutes, solicits Research Project Grant (R01) applications from qualified researchers to investigate the biology of the lymphatic system and potential new therapeutic implications. The purpose of this program announcement is to stimulate research on the biology of the lymphatic system at all biologic levels: molecular, cellular, tissue, organ, and whole body levels. Further, it includes research on innovations for identifying and intervening in lymphatic diseases across all age groups and disease states. Examples of potential areas of research pertinent to NCI participation in PAR-07-420 are listed in the announcements. Among the examples are a) Molecular characterization and comparison of normal and tumor lymphatic endothelia and their component cells, including identifications of molecular markers, secreted factors, and/or receptors; b) Determination of the functional status of tumor lymphatic vessels, e.g. the uptake and transport of fluid and macromolecules; c)Study of the interplay between angiogenesis and lymphangiogenesis; d) Design and validation of imaging modalities to visualize normal and tumor lymphatics.

See full description in the NIH Guide: PAR-07-420

See description of NCI areas of research interest: NOT-CA-07-022

NEUROIMAGING INFORMATICS SOFTWARE ENHANCEMENT FOR IMPROVED INTEROPERABILITY AND DISSEMINATION (multiple institutes) (R03) (PAR-07-417)

  • Release Date: July 25, 2007
  • Application Receipt Date: See dates below
  • Expiration Date: May 15, 2010
  • Contacts:
    Zohara Cohen, Ph.D.
    Tel: 301-451-4778
    E-mail: zcohen@mail.nih.gov
  • Letters of Intent Receipt Date(s): August 24, 2007; December 15, 2008; April 15, 2008; August 15, 2008, December 15, 2009; April 15, 2009; August 15, 2009; December 15 2010; and April 14, 2010
  • Application Submission/Receipt Date(s): September 24, 2007; January 15, 2008; May 15, 2008; September 15, 2008, January 15, 2009; May 15, 2009; September 15, 2009; January 15 2010; and May 14, 2010

This FOA intends to support modification and enhancement of existing neuroimaging informatics tools and resources that are hosted or being considered for inclusion into the NIH Neuroimaging Informatics Tools and Resources Clearinghouse (NITRC, www.nitrc.org, public release scheduled for October 2007). Examples of such tools include image segmentation, image registration, image processing pipelines, statistical analysis packages, spatial alignment and normalization algorithms, and data format translators. Resources include well-characterized test datasets, data formats, and databases, among others.

See full description in NIH Guide: PAR-07-417

Biology of Breast Pre-Malignancies (R01) (NCI) (RFA-CA-07-047)

  • Release Date: July 09, 2007
  • Application Receipt Date: November 14, 2007
  • Expiration Date: November 15, 2007
  • Contacts:
    Anne Tatum, NCI
    Phone: (301) 594-5371
    E-mail: tatema@mail.nih.gov

The purpose of this initiative is to stimulate multidisciplinary efforts focused on the characterization of the genetic, molecular, and/or cellular changes, and/or functional biology of pre-malignancy states of human breast cancer. The NCI solicits applications for research projects intended to facilitate the identification of those attributes of the earliest identifiable breast lesions that distinguish benign lesions from precancerous lesions. Applicants are encouraged to exploit resources and technologies that already exist, including imaging and nanotechologies. Projects taking advantage of information already available from well-validated animal model systems and quantitative modeling may also be appropriate. Two to three awards will be made.

URL: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-07-047.html

High-end Instrumentation Grant Program (S10) (NCRR) (PAR-07-383)

  • Release Date: June 13, 2007
  • Application Receipt Date: September 17, 2007
  • Expiration Date: September 18, 2007
  • Contacts:
    Marjorie A. Tingle, Ph.D., NCRR
    Phone: 301-435-0772
    E-mail: HEI@mail.nih.gov

The NCRR High-End Instrumentation Grant (HEI) program solicits applications from groups of NIH-supported investigators to purchase a single major item of equipment to be used for biomedical research that costs at least $750,000. The maximum award is $2,000,000. Instruments in this category include, but are not limited to, structural and functional imaging systems, macromolecular NMR spectrometers, high-resolution mass spectrometers, cryoelectron microscopes and supercomputers.

URL: http://grants.nih.gov/grants/guide/pa-files/PAR-07-383.html

INNOVATIONS IN BIOMEDICAL COMPUTATIONAL SCIENCE AND TECHNOLOGY (MULTIPLE ICS)(R01) (PAR-07-344)

  • Release Date: May 29, 2007
  • Application Receipt Date: See below
  • Expiration Date: January 25, 2009
  • Contacts:
    Peter Lyster, Ph.D., NIGMS
    Phone: 301-451-6446
    Email: lysterp@mail.nih.gov
  • Application Receipt Dates: May 24, 2007; September 24, 2007; January 24, 2008; May 24, 2008; September 24, 2008, January 24, 2009

The NIH is interested in promoting research and developments in computational science and technology that will support rapid progress in areas of scientific opportunity in biomedical research. The Institutes and Centers of the NIH offer support through the current solicitation for fundamental research in biomedical information science and technology as well as for the development of new informatics, computational and mathematical tools and technologies.

See full description in NIH Guide: PAR-07-344

INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARD (U54) (ROADMAP) (RFA-RM-07-007)

  • Release Date: May 22, 2007
  • Application Receipt Date: See below
  • Expiration Date: See below
  • Contacts:
    Anthony Hayward, Ph.D., NCRR
    Phone: 301-435-0790
    Email: haywarda@mail.nih.gov
  • Letters of Intent Receipt Date: September 24, 2007 (Extended to October 9, 2007 per NOT-RM-07-013)
  • Application Receipt Date: October 24, 2007 (Extended to November 7, 2007 per NOT-RM-07-013)
  • Expiration Date: October 25, 2007 (Extended to November 8, 2007 per NOT-RM-07-013)

The goal of the Institutional Clinical and Translational Science Award (CTSA) program is to transform the local, regional and national environment for clinical and translational science, thereby increasing the efficiency and speed of clinical and translational research. This transformation will be achieved by creating an academic home, which can be a center, department, or Institute (C/D/I), comprising faculty and programs that integrate clinical and translational science across multiple departments, schools, clinical and research institutes and hospitals. The C/D/I should provide clinical research resources including infrastructure and training to various disciplines in its institution (e.g., medicine, dentistry, nursing, pharmacy, public health, biostatistics, epidemiology, bioengineering) for the benefit of researchers, trainees, and research projects across multiple aspects of health promotion and disease prevention, pre-emption, and treatment studied by a wide range of NIH Institutes and Centers.

See full description in NIH Guide: RFA-RM-07-007

PAR-07-235: Continued Development and Maintenance of Software (R01) (Multiple ICs)

  • Release Date: February 23, 2007
  • Application Receipt Date: May 17, 2007 and September 13, 2007
  • Expiration Date: September 14, 2007
  • Contacts:
    Jennifer A Couch, Ph.D., NCI
    Phone: 301-435-5226
    Email: couchj@mail.nih.gov
  • Peer Review Date(s): October, 2007 and February, 2008

Biomedical research laboratories increasingly undertake a software development project to solve a problem of interest to that laboratory. These software packages sometimes become useful to a much broader community of users that can include translational and clinical researchers. The goal of this program announcement is to support the continued development, maintenance, testing and evaluation of existing software. The proposed work should apply best practices and proven methods for software design, construction, and implementation to extend the applicability of existing biomedical informatics/computational biology software to a broader biomedical research community.

URL: http://grants.nih.gov/grants/guide/pa-files/PAR-07-235.html

Nanoscience and Nanotechnology in Biology and Medicine (R01: PAR-07-270); (R21: PAR-07-271)

This funding opportunity (FOA) is aimed at enhancing nanoscience and nanotechnology research focused on problems in biology and medicine. Nanoscience and nanotechnology refer to research and development on the understanding and control of matter at a length scale of approximately 1 - 100 nanometers, where novel properties and functions occur because of the size. The National Cancer Institute (NCI) is interested in: 1. Early detection of the disease using imaging, 2. In vitro early diagnostics: multiplexed sensitive and specific sensors, 3. Multi-functional therapeutics and localized therapy delivery, and 4. Tools and approaches to interrogate, understand, and manipulate single cells, structures , and molecules.

URL:
http://grants.nih.gov/grants/guide/pa-files/PAR-07-270.html (R01)
http://grants.nih.gov/grants/guide/pa-files/PAR-07-271.html (R21)

Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (R01) (NIDDK, NIBIB, NIAAA) (PA-07-258)

  • Release Date: December 21, 2006
  • Application Receipt Date: Standard dates apply
  • Expiration Date: Expiration Date: September 2, 2008
  • Contacts:
    Contact: John Cole, Ph.D., NCI
    Phone: 301-496-1718
    Email: jc121b@nih.gov

Research activities are encouraged in the broad areas of etiology and etiologic mechanism(s) of liver cancer, including: Identification of viral and host factors; development of animal models and in vitro viral cultivation methods; development of prevention and control strategies, including chemoprevention, validation of markers, and clinical trials of promising agents; and conduct of treatment and diagnosis research, including imaging studies.

URL: http://grants.nih.gov/grants/guide/pa-files/PA-07-258.html

PA-07-260 & PA-06-281: Understanding the effects of emerging cellular, molecular, and genomic technologies on cancer health care delivery (R01) & (R21) (NCI)

  • Release Date: December 21, 2006
  • Application Receipt Date: Standard dates apply
  • Expiration Date: January 3, 2009
  • Contacts:
    Louise Wideroff, Ph.D., NCI
    Phone: 301-435-6823
    Email: wideroff@nih.gov

The purpose is to invite applications for health services research addressing utilization of cellular, molecular, and genetic or genomic (CMG) technologies in cancer care. The studies will assess CMG technologies in relation to: quality of care; organizational barriers and change factors in utilization; cost and cost-effectiveness; disparities in access and efficacy; monitoring of cross-sectional patterns of care and time trends; impact on existing standards of care, and; influence on cancer outcomes such as incidence, progression, mortality, survival, and quality of life. This funding opportunity specifically encourages research on commercially available CMG clinical tools already in use, as well as experimental tools in the later stages of development and/or in the regulatory approval pipeline.

See full description in NIH Guide: R01 PA-07-260; R21 PA-06-281

Pathogenesis And Treatment Of Lymphedema And Lymphatic Diseases (R01) (PA-07-165)

  • Release Date: December 14, 2006
  • Application Receipt Date: Multiple dates, see announcement
  • Expiration Date: December 31, 2009, unless reissued
  • Contacts:
    Suresh Mohla, Ph.D., NCI
    Phone: 301-435-1878
    Email: mohlas@mail.nih.gov

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research on the lymphatic system, to characterize its function on the molecular, cellular, tissue, organ, and intact organism levels and pathophysiologic mechanisms that cause disease, to develop new methods for imaging and/or quantitating lymph flow, and to discover new therapeutic interventions, including nursing, complementary and alternative treatments.

URL: http://grants.nih.gov/grants/guide/pa-files/PA-07-165.html

Ancillary Studies to the AD Neuroimaging Initiative (R01) (NIA, NIBIB) (PA-07-134)

  • Release Date: December 13, 2006
  • Application Receipt Date: Standard dates apply
  • Expiration Date: November 6, 2007
  • Contacts:
    Suresh Mohla, Ph.D., NCI
    Phone: 301-435-1878
    Email: mohlas@mail.nih.gov

This FOA invites research grant applications for ancillary studies to the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a multi-site, longitudinal, prospective, naturalistic study of normal cognitive aging, mild cognitive impairment (MCI), and early Alzheimer’s disease (AD). The ADNI is collecting, processing, and storing serial blood, CSF, and urine samples in the three groups for analyses for potential biomarkers of disease progression, including genomic, proteomic, and metabolomic markers that can be correlated with clinical, neuropsychological, and imaging data.

URL: http://grants.nih.gov/grants/guide/pa-files/PA-07-134.html

Innovations in Biomedical Computational Science and Technology Initiative (SBIR [R43/R44]) (PAR-07-160)
Innovations in Biomedical Computational Science and Technology Initiative (STTR [R41/R42]) (PAR-07-161)

BISTI targets support for fundamental research in biomedical computing science and technology as well as the development and application of new biocomputing tools or technologies for a particular area(s) of scientific opportunity in biomedical research.

Programs may target one or multiple areas of biomedical computing that will enable progress in biomedical research. Examples of data types that could be considered include but are not limited to genomic sequences, biomedical images, qualitative descriptors for health and social science, remote sensing and geospatial images, and pathway data.

URLs:
http://grants.nih.gov/grants/guide/pa-files/PAR-07-160.html (SBIR)
http://grants.nih.gov/grants/guide/pa-files/PAR-07-161.html (STTR)

Shared Instrumentation Grant Program (S10) (NCRR) (PAR-07-105)

  • Release Date: December 06, 2006
  • Application Receipt Date: March 21, 2007
  • Expiration Date: March 22, 2007
  • Contacts:
    Marjorie A. Tingle, Ph.D., NCRR
    Phone 301-435-0772
    Email: SIG@mail.nih.gov

The NCRR Shared Instrument Grant (SIG) program solicits applications from groups of NIH-supported investigators to purchase or upgrade commercially available instruments that cost at least $100,000. The maximum award is $500,000. Types of instruments supported include confocal and electron microscopes, biomedical imagers, mass spectrometers, DNA sequencers, biosensors, cell sorters, X-ray diffraction systems, and NMR spectrometers among others.

URL: http://grants.nih.gov/grants/guide/pa-files/PAR-07-105.html

NOT-FD-06-001: Notice of Availability of Funds to Support Clinical trials on the Safety and Effectiveness of Products for Rare Diseases (FDA)

  • Release Date: November 27, 2006
  • Application Receipt Date: February 7, 2007
  • Expiration Date: N/A
  • Contacts:
    Debra Y. Lewis, O.D.
    Email: debra.lewis@fda.hhs.gov
    Phone: 301-827-0059

The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OPD) is pleased to announce the availability of funds for fiscal year (FY) 2008 grant awards to support clinical trials on the safety and effectiveness of products for rare diseases and conditions. Contingent on availability of FY 2007 and FY 2008 funds, it is anticipated that $14.2 million will be available for new applications, competing awards, and non competing continuation awards. These studies are intended to provide acceptable data to the FDA that will substantially contribute to the approval of new products, or new indications for already marketed products. In the FDA OPD grants program, products for rare diseases and conditions (orphan products) are defined as drugs, biologics, medical devices, and medical foods indicated to treat or diagnose a rare disease or condition with a prevalence of fewer than 200,000 people in the United States.

See Notice in NIH Guide: NOT-FD-06-001

PAR-06-540: Cancer Education Grants Program (R25)

  • Release Date: August 30, 2006
  • Application Receipt Date: Multiple dates, see announcement
  • Expiration Date: March 2, 2008
  • Contacts:
    Lester S. Gorelic, Ph.D.
    Phone: 301-496-8580
    Email: gorelicl@mail.nih.gov

This Funding Opportunity Announcement (FOA) uses the NIH Research Education (R25) grant mechanism to support the following types of programs: innovative educational programs intended to motivate biomedical and other health science students to pursue cancer related careers; short courses to update cancer research scientists in new scientific methods, technologies and findings; training of cancer care clinicians and community health care providers in evidence-based cancer prevention and control approaches; development of effective innovative education (dissemination) approaches to translate knowledge gained from science (discovery) into public health and community applications (delivery).

Because the nature and scope of the proposed research education program will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.

The total project period for an application submitted in response to this funding opportunity may not exceed five years. Direct costs are limited to $300,000 per year.

See full description in NIH Guide: PAR-06-540

PA-06-533: Functional Links between the Immune System, Brain Function and Behavior (R21) (NIMH, NCI, NIA, NIAMS, NIBIB, NIDA, NINDS)

  • Release Date: August 22, 2006
  • Application Receipt Date: Multiple dates, see announcement.
  • Expiration Date: September 2, 2008
  • Contacts:
    Paige McDonald, Ph.D.
    Phone: 301-435-5037
    Email: mcdonalp@mail.nih.gov

The potent effects of neuroimmune molecules in the brain are mediated through multiple signaling pathways. However, details regarding the extent, routes, or mechanisms whereby immune signaling affects the brain in either normal conditions or during immune challenge and inflammation are largely unexplored. The purpose of this FOA is to identify research opportunities that may help to bridge the gap in understanding how immune cells and their mediators affect brain development, function and behaviors related to cognition and mood.

See full description in NIH Guide: PA-06-533

PA-06-461, PA-06-462, & PA-06-463: Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21, R33, & R21/R33) (NIMH, NIA, NIAAA, NIBIB, NIDA, NINDS)

  • Release Date: August 07, 2006
  • Application Receipt Date: Multiple dates, see announcement
  • Expiration Date: July 2, 2009
  • Contacts:
    4 different contacts for the different ICs

This FOA is intended to stimulate the development of radioligands for molecular targets (e.g., receptors, cell adhesion molecules, intracellular messengers, and disease related proteins) that are of broad interest to the scientific community. The widespread availability and use of these radioligands are expected to: 1) accelerate research on identifying and characterizing the neural circuits and pathways implicated in the pathophysiology of brain disorders (especially mental and behavioral disorders, substance abuse, neurodegenerative disorders, and pediatric brain disorders) and brain changes with age, and 2) facilitate the identification of new therapeutic targets and the development of new compounds as potential therapeutic agents. Research partnerships among investigators in both academia and pharmaceutical and biotechnology industries are encouraged to more rapidly develop PET and SPECT radiotracers and apply neuroimaging in drug discovery, biomarker development//qualification, and pathophysiological studies.

Molecular targets for which radioligands (agonist and antagonist ) are needed include, but are not limited to, the following. Please contact program staff to determine program priorities and molecular targets of interest to specific NIH Institutes or refer to the Internet addresses listed above for each of the participating NIH Institutes.

  • Receptors: adenosine; adrenergic: alpha 1, alpha 2; cannabinoid: CB1, CB2; corticotropin releasing hormone: CRF R1, CRF R2; dopamine: D1, D3, D4, D5; estrogen; GABA A subunits; GABA ion channel; GABA B; glutamatergic, glycine site; metabotropic glutamate subtypes; muscarinic subunits; neurokinin receptors: NK1, NK2, NK3; neuronal nicotinic receptor subunits: alpha 7 & alpha 4 beta 2; NMDA subunits; opioid receptors: mu, delta, kappa; serotonin: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2C, 5-HT5, 5-HT6, 5-HT7; voltage gated ion channels: Ca, Na, K - M current proteins.
  • Transporters: vesicular ACh; GABA; glutamate; glycine; glutamine; NET; VMAT, excitatory amino acid transporters.
  • Markers for glia, glial activation, and glial cell death.
  • Enzymes: choline acetyltransferase; dopamine beta-hydroxylase; GABA transaminase; glutamic acid decarboxylase; glutaminergic; phosphodiesterases; tyrosine hydroxylase.
  • Intracellular targets: abnormal proteins or protein aggregates including synuclein, prion protein, amyloid or tau deposition; diacylglycerol; gene expression/transcription markers; markers of neurogenesis or neuronal cell death; markers of mitochondrial function; lipid metabolism; neuroinflammatory markers: cytokines, COX inhibitors; peptidases; phosphatases; phospholipases; protein kinases; stem cells.

See full description in NIH Guide: R21 PA-06-461; R33 PA-06-462; R21/R33 PA-06-463

PA-06-512: Mentored Clinical Scientist Research Career Development Award (K08)

  • Release Date: August 07, 2006
  • Application Receipt Date: Multiple dates, see announcement
  • Expiration Date: September 2, 2009
  • Contacts:
    David J. Eckstein, Ph.D. (NCI)
    Phone: 301-496-8580
    Email: Eckstein@mail.nih.gov

The Mentored Clinical Scientist Research Career Development Award (K08) represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. Individuals with a clinical doctoral degree interested in pursuing a career in patient-oriented research should refer to the NIH Mentored Patient-Oriented Research Career Development Award (K23).

An award is for a period of 3 to 5 years and provides support for salary and research-related costs. The amount funded as salary for a career development award varies among the NIH participating Institutes and Centers (ICs). Therefore, the applicant is strongly advised to contact the relevant IC for any distinct guidelines, requirements, and allowable funds (http://grants.nih.gov/grants/guide/contacts/pa-06-512_contacts.htm).

See full description in NIH Guide: PAR-06-512

PAR-06-475: Nanoscience and Nanotechnology in Biology and Medicine(R21) (Multiple ICs)

  • Release Date: July 10, 2006
  • Application Receipt Date: August 18, 2006
  • Expiration Date: August 19, 2006

This funding opportunity announcement (FOA) is aimed at enhancing nanoscience and nanotechnology research approaches that have the potential to make valuable contributions to biology and medicine. The purpose of this initiative is to stimulate cross-cutting, integrative research in these fields of science and technology. In particular, this initiative invites research on: i) the creation and use of structures, devices and systems that have novel properties and functions because of their small size, that may be used to achieve a fundamental understanding of biological processes and /or contribute to disease detection, therapy, or prevention; ii) conception and fabrication of devices, that will effectively detect and analyze nanoscale entities of relevance to biomedicine; and iii) the study of biological systems at the nanoscale for the explicit purpose of using that information to develop nanotechnologies and nanostructured materials that will in turn benefit biology and medicine. The research projects that will be most responsive to this FOA will require interdisciplinary collaborations among investigators with expertise in a range of disciplines, including but not limited to engineering, physics, chemistry, cellular and molecular biology, materials and computer science. Applications submitted in response to this PA may propose hypothesis-driven, discovery-driven, developmental, or design-directed research.

See full description in NIH Guide: PAR-06-475

NOT-OD-06-081: NIH Offers Commercialization Assistance Program to SBIR Phase II Awardees

  • Release Date: July 10, 2006
  • Application Receipt Date: July 31, 2006
  • Expiration Date: N/A

The CAP consists of training workshops, individual mentoring and consulting sessions, and it culminates with an opportunity for companies to present their business opportunities to potential investors and strategic partners at the NIH Life Sciences Showcase. Participation is free; however, selected participants are responsible for their travel expenses to attend two required workshops and the optional showcase. Detailed program information, eligibility requirements, and application instructions are available at http://www.larta.org/nihcap/NIHCAP-ProgramDescription.pdf. The deadline for submitting an application is July 31, 2006. Approximately 125 companies will be selected to participate in this year’s NIH CAP and will be notified by August 14, 2006.

See full description in NIH Guide: NOT-OD-06-08

NIH-PAR-06-075: Nanoscience and Nanotechnology in Biology and Medicine

  • Release Date: July 10, 2006
  • Application Receipt Date: August 18, 2006
  • Expiration Date: August 19, 2006
  • Contacts:
    Jeff Schloss, Ph. D., NHGRI
    Phone: 301-435-5538
    Email: schlossj@exchange.nih.gov

See full description in NIH Guide: NIH PAR-06-475

PAR-06-459: Bioengineering Research Partnerships (BRP) [R01]

  • Release Date: June 26, 2006
  • Application Receipt Date: N/A
  • Expiration Date: N/A

The primary objective of this program announcement is to encourage basic, applied, and translational bioengineering research that could make a significant contribution to improving human health. Bioengineering integrates physical, engineering, and computational science principles for the study of biology, medicine, behavior, or health. It advances fundamental concepts, creates knowledge from the molecular to the organ systems level, and develops innovative biologicals, materials, processes, implants, devices, and informatics approaches for the prevention, diagnosis, and treatment of disease, for patient rehabilitation, and for improving health. Some BRP projects may propose research that could lead to a novel device as a product. Partnership with companies that have relevant expertise or that may eventually be involved in commercialization is appropriate under the BRP program.

A second objective is to encourage collaborations and partnerships among the allied quantitative and biomedical disciplines. A BRP must bring together the necessary physical, engineering, and computational science expertise with biological or clinical expertise and resources to address a significant area of bioengineering research within the mission of the NIH. In addition to the benefits to be derived from the research, the collaborations and partnerships can create opportunities for trans-disciplinary communication and training for a new generation of scientists capable of interacting across traditional technical boundaries.

Applications for a BRP award should focus bioengineering research on an area of basic, applied, translational, behavioral, or clinical research that supports the missions of the participating NIH institutes and centers and where progress is likely to make a significant contribution to improving human health. Some NIH institutes and centers have indicated that they will only consider BRP applications in specific focus areas or use different budget caps. These institutes and focus areas are available at http://www.becon.nih.gov/becon_brpareas.htm.

See full description in NIH Guide: PAR-06-459

PAR-06-455: The NCI Transition Career Development Award (K22)

  • Release Date: June 16, 2006
  • Application Receipt Date: Standard dates apply
  • Expiration Date: July 2, 2009
  • Contacts:
    Dr. David J. Eckstein, NCI
    Phone: 301-496-8580
    Email: eckstein@mail.nih.gov

The major objective of the NCI Transition Career Development Award program is two-fold: (i) to provide a mechanism for stabilizing the career tracks of the most promising of investigators while they are establishing their first independent research programs and (ii) to create equal access to extramural career development opportunities to postdoctoral scientists in basic human cancer research working as Federal employees.

See full description in NIH Guide: PAR-06-455

PA-06-468: Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32)

The objective of the NRSA program is to provide predoctoral and postdoctoral research training opportunities for individuals interested in pursuing research careers in biomedical, behavioral and clinical research. Each NIH Institute and Center has a unique scientific purview and different program goals and initiatives that evolve over time. It is therefore critical that all applicants consult with the scientific/research contact at the relevant NIH Institute or Center for current information about program priorities and policies before preparing an application. This action is of utmost importance because applications with marginal or no relevance to the NIH awarding components participating in this funding opportunity announcement will not be accepted for review or considered for funding.

See full description in NIH Guide: PA-06-468

PAR-06-451: Quick-Trials for Novel Cancer Therapies: Exploratory Grants (R21)

  • Release Date: June 09, 2006
  • Application Receipt Date: August 9, 2006; December 9, 2006; April 9, 2007; July 9, 2007; November 9, 2007
  • Expiration Date: December 10, 2007 (unless reissued) Reissued as PAR-08-025 New Expiration Date: Nov 10, 2010
  • Contacts:
    Dr. Roy Wu, NCI
    Phone: 301-496-8866
    Email: wur@ctep.nci.nih.gov

This FOA is aimed at providing a new approach in the grant application process by offering a rapid turnaround from application submission to funding. Features of this initiative include a modular grant application and award process, inclusion of the clinical protocol within the grant application, and an accelerated peer review with the goal of issuing new awards within 6 months of application receipt. Inclusion of the complete clinical protocol within the grant application is intended to simplify the application process by eliminating the need to duplicate protocol details in the Research Plan section and to insure proper peer review of the application. In addition, QUICK-TRIAL applications do not require extensive preliminary data in the grant application and support exploratory translational and clinical research studies involving cancer prevention, chemotherapy, and rapid development and application of novel clinical cancer therapies, including image-guided therapeutic procedures.

See full description in NIH Guide: PAR-06-451

Reissue Announcment: PAR-08-025

PAR-06-411: Exploratory Innovations in Biomedical Computational Science and Technology (R21)

  • Release Date: May 15, 2006
  • Application Receipt Date: See below
  • Expiration Date: January 25, 2009
  • Contacts:
    http://www.bisti.nih.gov/R01-contacts.cfm
  • Application Receipt/Submission Date(s): June 24, 2006; September 24, 2006; January 24, 2007; May 24, 2007; September 24, 2007; January 24, 2008; May 24, 2008; September 24, 2008, January 24, 2009

The NIH is interested in promoting research and developments in computational science and technology that will support rapid progress in areas of scientific opportunity in biomedical research. As defined here, biomedical computing or biomedical information science and technology includes database design, graphical interfaces, querying approaches, data retrieval, data visualization and manipulation, data integration through the development of integrated analytical tools, and tools for electronic collaboration, as well as computational and mathematical research including the development of structural, functional, integrative, and analytical models and simulations.

See full description in NIH Guide: PAR-06-411

Interdisciplinary Research Consortium (U54) Preapplication for Interdisciplinary Research Consortium (X02)

  • Release Date: April 10, 2006
  • Application Receipt Date: N/A
  • Expiration Date: N/A

Dates: LOI: March 21, 2006; Pre-application: April 18, 2006 — Use SF-424 Electronic Submission.

The Interdisciplinary Research Implementation Group will invite applications for Interdisciplinary Research Consortia from among those that submit a pre-application in response to PAR-06-122. This RFA with Limited Eligibility for a full consortium is released early to aid those who are writing a pre-application. Only those selected through a peer review of their pre-application are eligible to apply for a full Interdisciplinary Research Consortium. The purpose of this program is to support interdisciplinary approaches to solving significant and complex biomedical problems, particularly those that have been resistant to traditional approaches. These applications must hold the promise of leading to new research approaches to improving human health. Interdisciplinary consortia are expected to identify an important biomedically relevant problem, evaluate why previous approaches have not worked, justify why the proposed interdisciplinary approach will work, identify the methods that will keep the interdisciplinary team focused and coordinated, and propose a timeline. The review criteria will involve both the significance of the problem as well as the interdisciplinary nature of the approach to solving the problem. Applications will have to be strong in both of these areas. A successful interdisciplinary approach is defined as combining aspects of individual disciplines to provide a new conceptual approach to solving a problem that is likely to yield insights that could not have been achieved by an isolated laboratory or using a multi-disciplinary approach.

Consortium RFA
Pre-application
Addendum

RFA-CA-06-014: Tumor Microenvironment Network (TMEN) (U54)

  • Release Date: April 10, 2006
  • Application Receipt Date: May 10, 2006
  • Expiration Date: N/A

Letter of Intent Receipt Date: April 10, 2006
The NCI invites cooperative agreement and NIH intramural applications from groups of investigators interested in becoming components of the NCI Tumor Microenvironment Network (TMEN). The main objective is to delineate mechanisms of tumor-stroma interactions in human cancer and to generate a comprehensive understanding of composition of the stroma in normal tissues as well as its roles in tumor initiation, progression, and metastasis.

See full description in NIH Guide: RFA-CA-06-014

RFA-RM-06-007: Nanomedicine Development Centers (PN2)

  • Release Date: April 10, 2006
  • Application Receipt Date: June 23, 2006
  • Expiration Date: N/A

Concept Approval Letter Receipt Date: March 15, 2006
Nanomedicine is one of nine major initiatives included in the NIH Roadmap. Because Nanomedicine is an emerging biomedical discipline, the NIH engaged the biomedical research community to help define and develop concepts and a framework to stimulate work in this field. A two-year planning process, (see http://grants1.nih.gov/grants/guide/rfa-files/RFA-RM-04-018.html) culminated in the establishment of a collaborative national network of Nanomedicine Development Centers (NDC). The first four centers were awarded in fiscal year 2005. The current RFA solicits applications for additional centers that will expand the network by addressing complementary models, topics, medical targets, and approaches to the work of funded centers.

See full description in NIH Guide: RFA-RM-06-007

Concept Approval Letter Evaluation Information

PA-06-149: Innovative and Exploratory Research in Digestive Diseases and Nutrition (R21) (NIDDK, NCI, ODS)

  • Release Date: April 10, 2006
  • Application Receipt Date: March 2, 2006
  • Expiration Date: November 15, 2006

The NIDDK and the Division of Cancer Prevention at the NCI invite applications through the exploratory/developmental (R21) grant mechanism from investigators with research interests in gastroenterology, hepatology, obesity, and nutrition and that serve the mission of NIDDK and NCI. The aim of this funding opportunity is to stimulate the application of highly novel approaches to important areas of digestive diseases (including associated cancers) and nutrition research. Areas of special interest in this funding opportunity include development of novel non invasive imaging methods to study function of the gastrointestinal tract, liver, pancreas and adipose tissue and pathogenic processes such as fibrosis, inflammation, hyperplasia, fat body accumulation.

See full description in NIH Guide: PA-06-149

PAR-06-313: Cancer prevention research small grant program (R03) (NCI)

  • Release Date: April 04, 2006
  • Application Receipt Date: July 20, 2006; November 20, 2006; March 20, 2007; July 21, 2007; December 20, 2007
  • Expiration Date: December 21, 2007
  • Contacts:
    Padma Maruvada, Ph.D. (Early Detection)
    Phone: 301-496-3893
    Email: maruvadp@mail.nih.gov

The Division of Cancer Prevention of the NCI invites applications that address developmental research in chemoprevention agent development, biomarkers, early detection, and nutrition science. However, it is important to note that this funding opportunity does not include applications that are focused on treatment, etiology, or treatment-related quality of life studies that are population based. This Small Grants Program is designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of research expertise in cancer prevention research. It is anticipated that this Small Grant Program may lead to the submission of subsequent individual research project grants (R01).

See full description in NIH Guide: PAR-06-313

PA-06-314: Pilot Studies in Pancreatic Cancer (R03) (NCI)

This funding opportunity is intended to promote innovative research across multiple disciplines for better understanding of the biology, etiology, detection, prevention, and treatment of pancreatic cancer.

See full description in NIH Guide: PA-06-314

PAR-06-311: Imaging - science track award for research transition (I/START) (R03) (NIDA)

  • Release Date: March 31, 2006
  • Application Receipt Date: Standard dates apply
  • Expiration Date: January 3, 2009
  • Contacts:
    L R Stanford, Ph.D.
    Phone: 301-402-3869
    Email: lstanfor@nida.nih.gov
  • Letters of Intent Receipt Date(s): 30 days prior to the application submission/receipt date

This Funding Opportunity Announcement (FOA) issued by the NIDA is intended to facilitate the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs.

See full description in NIH Guide: PAR-06-311

PA-06-299: Exploratory studies in cancer detection, diagnosis, and prognosis (R21)

The objective of this FOA is to encourage grant applications for exploratory (R21) grants from individuals who are interested in testing new ideas that may advance progress in cancer detection, diagnosis, and prognosis. Imaging studies are not intended to be funded under this initiative. For imaging initiatives, call the Cancer Imaging Program staff.

See full description in NIH Guide: PA-06-299

RFA-AI-06-030: Radionuclide decorporation agents for radiation/nuclear emergencies: project bioshield (R01) (NIAID)

  • Release Date: March 30, 2006

This is a funding opportunity announcement (FOA) to accelerate the development of safe and effective products to remove radionuclides from the body (decorporation) following nuclear contamination from any source. Specifically, candidate products will demonstrate an increase in efficiency and rate of radionuclide elimination from the body after contamination due to ingestion, inhalation or transdermal absorption.

See full description in NIH Guide: RFA-AI-06-030

PA-06-295: Etiology, prevention, and treatment of hepatocellular carcinoma (R21) (NCI, NIAAA, NIBIB, NIDDK)

  • Release Date: March 29, 2006
  • Application Receipt Date: Standard dates apply
  • Expiration Date: September 8, 2008
  • Contacts:
    John Cole, Ph.D.
    Phone: 301-496-1718
    Email: jc121b@nih.gov

    Heng Xie, M.D., M.P.H., Ph.D
    Phone: 301-496-8866 or 301-496-6512
    Email: XieHe@mail.nih.gov

The several institutes are interested in receiving grant applications that address the etiology and etiologic mechanisms of hepatocellular carcinoma (HCC) and development of animal models, novel approaches to prevent this malignancy, and therapeutic or diagnostic studies aimed at establishing reliable prognostic indicators for disease progression and/or minimizing morbidity and mortality associated with this malignancy.

See full description in NIH Guide: PA-06-295

PA-06-278: Neurotechnology research, development, and enhancement (R21) (NIMH, NIA, NIBIB, NICHD, NIDA, NIDCD, NINDS)

  • Release Date: March 24, 2006
  • Application Receipt Date: Standard dates apply
  • Expiration Date: July 2, 2009
  • Contacts:
    http://www.nih.gov

The purpose of this Funding Opportunity Announcement (FOA) is to encourage submission of new Exploratory/Developmental (R21) grant applications to research and develop innovative technologies, methodologies, or instrumentation for basic or clinical studies of the brain or behavior in human or non-human animals. Also solicited are applications for support to research, develop, and significantly enhance existing technologies that are important to understanding the brain or behavior.

See full description in NIH Guide: R21 PA-06-278

PAR-05-124: High-End Instrumentation Grant Program (NCRR)

  • Release Date: September 06, 2005
  • Application Receipt Date: September 20,2005

HIGH-END INSTRUMENTATION GRANT PROGRAM (NCRR) (PAR-05-124)

Letters of Intent Receipt Date(s): August 15, 2005

The NCRR High-End Instrumentation Grant (HEI) program solicits applications from groups of NIH-supported investigators to purchase a single major item of equipment to be used for biomedical research that costs at least $750,000. The maximum award is $2,000,000. Instruments in this category include, but are not limited to, structural and functional imaging systems, macromolecular NMR spectrometers, high-resolution mass spectrometers, cryoelectron microscopes and supercomputers. The NCRR intends to commit approximately $21 million in FY2006 to fund approximately 11-16 new awards. Awards are for one year and for direct costs only. Cost sharing is not required. Since the cost of the various instruments will vary, it is anticipated that the size of the award also will vary. This Program Announcement will use the NIH S10 mechanism.

See full description in NIH Guide: PAR-05-124

PAR-05-063: Collaborations with National Centers for Biomedical Computing

COLLABORATIONS WITH NATIONAL CENTERS FOR BIOMEDICAL COMPUTING (PAR-05-063) (NCI)

Letters of Intent Receipt Date(s): April 19, 2005; December 19, 2005; same through 2008

Application Receipt Dates(s): May 17, 2005; January 17, 2006; same through 2008

The purpose of this program announcement is to provide support for investigators working in collaboration with the NIH National Centers for Biomedical Computing (NCBC) using the R01 mechanism. Details about the specific NIH NCBCs already awarded can be found at http://www.bisti.nih.gov/ncbc/.

See full description in NIH Guide: PAR-05-063

RR-05-001: Technology Development for Biomedical Applications (NCRR)

  • Release Date: September 06, 2005
  • Application Receipt Date: June 22, 2005 and October 19, 2005
  • Expiration Date: N/A
  • Contacts:
    Gregory K. Farber, Ph.D., NCRR
    Email: farberg@mail.nih.gov
    Phone: 301-435-0778

    David M. Balshaw, Ph.D., NIEHS
    Email: balshaw@niehs.nih.gov), 9190541-2448

TECHNOLOGY DEVELOPMENT FOR BIOMEDICAL APPLICATIONS (NCRR)(RFA-RR-05-001)

Application Receipt Date(s): June 22, 2005 and October 19, 2005

The purpose of this request for applications (RFA) is to invite innovative applications for (1) the development of new and improved instruments or devices, (2) the development of new methodologies using existing instruments, or (3) the development of software related to instrumentation. Any of these projects should propose tools, methodologies, or software that can be used by a wide range of biomedical or clinical researchers.

See full description in NIH Guide: RFA-RR-05-001

PAR-05-122: Development of PET and SPECT Ligands for Brain Imaging (SBIR/STTR AWARD)

  • Release Date: September 06, 2005
  • Application Receipt Date: February 1, 2005; June 1, 2005; October 1, 2005

DEVELOPMENT OF PET AND SPECT LIGANDS FOR BRAIN IMAGING (SBIR/STTR AWARD) (NIMH, NIDCD, NIDA, NIA, NINDS) (PA-05-122)

Standard receipt dates apply.

This initiative is intended to stimulate the commercial development of novel radioligands for positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging in human brain, and to incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies. The NIH institutes listed in this PA are specifically interested in the development of radioligands for molecular targets (e.g., receptors, cell adhesion molecules, intracellular messengers, and disease related proteins) that are of broad interest to the scientific community. These radiotracers will be used for neuroimaging as well as potential biological markers and surrogate endpoints for translational and clinical research, drug discovery and development, and clinical trials. Also appropriate for this PA are applications proposing research and development of new technologies for radiotracer development.

See full description in NIH Guide: PA-05-122

PA-05-116: Pilot Studies in Pancreatic Cancer (NCI)

  • Release Date: September 06, 2005
  • Application Receipt Date: February 1, June 1, October 1
  • Expiration Date: N/A
  • Contacts:
    see announcement for contacts according to subject

PILOT STUDIES IN PANCREATIC CANCER (NCI) (PA-05-116)

The Division of Cancer Control and Population Sciences (DCCPS), Division of Cancer Biology (DCB), Division of Cancer Prevention (DCP), and Division of Cancer Treatment and Diagnosis (DCTD) of the National Cancer Institute (NCI) invite Exploratory Grant (R21) and Small Grant (R03) applications relating to the biology, etiology, detection, prevention, and treatment of pancreatic cancer. These are short-term awards intended to provide support for pilot projects, testing of new techniques, and/or development of innovative projects that could provide a basis for more extended research.

See full description in NIH Guide: PA-05-116

Japan Society Fellowships

  • Release Date: September 06, 2005
  • Application Receipt Date: October 31, 2005
  • Expiration Date: See below
  • Contacts:
    Maria "Mili" Ferreira, JSPS Program Assistant
    Division of International Training and Research
    Fogarty International Center
    Tel: 301 594-9778
    Fax: 301 402-0779
    E-mail: ferreima@mail.nih.gov

The Japan Society for the Promotion of Science (JSPS) conducts fellowship programs for foreign researchers to promote international cooperation in and mutual understanding through scientific research in Japan. Research applications are accepted at the Fogarty International Center (FIC), National Institutes of Health (NIH), which acts as a nominating authority for JSPS programs.

JSPS Invitation Fellowships

JSPS conducts short-term (14-60 days) and long-term (61 days -10 months) programs under the Invitation Fellowship Program. The fellowship is funded by a subsidy from the Japanese government, to promote international cooperation and mutual understanding through scientific research. Scientists employed at designated Japanese research institutions and laboratories to invite fellow researchers from the U.S. to Japan to participate in cooperative activities. Application deadline: October 31, 2005

JSPS Postdoctoral Fellowships

The JSPS conducts short-term (15 days - 11 months) and long-term (12-24 months) Postdoctoral Fellowships for Foreign Researchers, to assist promising and highly-qualified young researchers wishing to conduct research in Japan. Postdoctoral Fellowship (short-term) Application deadline: October 31, 2005; Postdoctoral Fellowship (long-term) Application deadline: June 30, 2005

Contact: Maria "Mili" Ferreira, JSPS Program Assistant, Division of International Training and Research, Fogarty International Center, Tel: 301 594-9778; Fax: 301 402-0779; e-mail: ferreima@mail.nih.gov

Fogarty International Center

PAR-05-145: Established Investigator Award In Cancer Prevention & Control (NCI)

  • Release Date: July 28, 2005
  • Application Receipt Date: Standard dates apply for K award
  • Expiration Date: January 8, 2010
  • Contacts:
    Mary C. Blehar, NCI
    Phone: 301-496-8580
    Email: mblehar@mail.nih.gov

ESTABLISHED INVESTIGATOR AWARD IN CANCER PREVENTION & CONTROL (NCI) (PAR-05-145)

Standard application dates.

The objective of the NCI Established Investigator Award in Cancer Prevention and Control (K05) is to provide qualified researchers with protected time to devote to research and mentoring. The award is designed for established scientists who have already demonstrated a sustained, high level of research and mentoring productivity and who need K05 support to continue these activities. The award provides partial salary support for up to 5 years and for up to 50 percent effort. It is renewable for one additional 5-year period.

See full description in NIH Guide: PAR-05-145

PA-05-143: Mentored Patient-Oriented Research Career Development Award (K23)

MENTORED PATIENT-ORIENTED RESEARCH CAREER DEVELOPMENT AWARD (K23) (PA-05-143)

Standard receipt dates apply.

The goal of the Mentored Patient-Oriented Research Career Development Award (K23) program is to ensure a future cadre of well-trained scientists working in POR areas who will become competitive for NIH research project (R01) grant support. The specific objectives of the Mentored Patient-Oriented Research Career Development Award are to: 1)encourage research-oriented clinicians to develop independent research skills and gain experience in advanced methods and experimental approaches needed to become an independent investigator conducting patient-oriented research; 2) increase the pool of clinical researchers who can conduct patient-oriented studies, capitalizing on the discoveries of biomedical research and translating them to clinical settings; 3) support the career development of investigators who have made a commitment to focus their research endeavors on patient-oriented research.

See full description in NIH Guide: PA-05-143

PAR-04-155: Exploratory/Developmental Grants for Quick-Trials for Novel Cancer Therapies (R21)

  • Release Date: August 31, 2004
  • Application Receipt Date: See Below
  • Contacts:
    Keyvan Farahani, Ph.D.
    Email: farahank@mail.nih.gov
    Phone: 301-451-2651
  • Application receipt dates: December 9, 2004; April 9, 2005; August 9, 2005; December 9, 2005; April 9, 2006; August 9, 2006; December 9, 2006; April 9, 2007; August 9, 2007; December 9, 2007

See full description in NIH Guide: NIH PAR-06-475

RFA: CA-05-002: Innovative Technologies for Molecular Analysis of Cancer

  • Release Date: December 17, 2003
  • Application Receipt Date: February 17, 2004; June 17, 2004; October 18, 2004
  • Expiration Date: N/A
  • Contacts:
    Barbara Y. Croft, Ph.D.
    Email: bc129b@nih.gov
    Phone: 301-496-9531

The National Cancer Institute (NCI) invites applications for research projects proposing the development of highly innovative cancer relevant technologies. Technology encompasses methods and tools that enable research, including, but not limited to, instrumentation, techniques, and devices. Technology is distinct from resources such as databases, reagents, and tissue repositories. This initiative will employ separate discovery (R21) and development (R33) awarding mechanisms. The R21 application will emphasize the high risk, high innovation feasibility phase and potential impact. The development (R33) phase application will have to contain proof of the feasibility of the proposed technology. Under this RFA, applicants must submit either an R21 application or a fully developed R33 application, according the guidelines below. The R21 may not exceed $100,000 direct costs per year for up to 2 years. The proposed R33 project period may be up to a maximum of 3 years. This program will run in parallel with a program of identical scientific scope CA-05-006 that will utilize the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) mechanisms.

  • Letter of Intent Receipt Date(s): January 16, 2004; May 17, 2004; September 17, 2004

See full description in NIH Guide: CA-05-002

RFA: CA-05-003: Application of Emerging Technologies for Cancer Research

  • Release Date: December 17, 2003
  • Application Receipt Date: February 17, 2004; June 17, 2004; October 18, 2004
  • Expiration Date: N/A
  • Contacts:
    Barbara Y. Croft, Ph.D.
    Email: bc129b@nih.gov
    Phone: 301-496-9531

The National Cancer Institute (NCI) invites applications for research projects to evaluate the usefulness of emerging technologies that are ready for initial application to clinical or biological questions in cancer research. Projects should be designed to demonstrate that the technology is robust and yields reproducible measurements. Projects should also be designed to gather preliminary data to support the use of the technology in a future project(s) with a clinical or biological focus. This RFA will use NIH R21/R33 Phased Innovation Award and the R33 Exploratory/Developmental Phase II award mechanisms. Under this RFA, applicants can submit either a combined R21/R33 (Phased Innovation Award) application or the R33 application alone; applications for R21 support alone will not be accepted. The total project period for an application submitted in response to this RFA may not exceed the following duration: R33, 3 years; combined R21/R33 application, 4 years. In the combined application, the R21 phase cannot extend beyond 2 years. For combined R21/R33 applications, the R21 phase may not exceed $100,000 direct costs per year. This program will run in parallel with a program of identical scientific scope (RFA CA-05-007) that will utilize the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) mechanisms.

  • Letter of Intent Receipt Date(s): January 16, 2004; May 17, 2004; September 17, 2004

See full description in NIH Guide: RFA: CA-05-003

NIH PAR-04-023: Bioengineering Research Partnership Programs

  • Release Date: November 18, 2003
  • Application Receipt Date: January 20, 2005; May 20, 2005; September 20, 2005; January 20, 2006; and May 22, 2006
  • Expiration Date: May 23, 2006

See full description in NIH Guide: NIH PAR-04-023

BAA: N01-CO-47010-16: Novel Technologies for Noninvasive Detection, Diagnosis and Treatment of Cancer

  • Release Date: October 21, 2003
  • Application Receipt Date: January 21, 2004
  • Contacts:
    Annmarie Keane
    Phone: 301-496-8620
    Email: ak155a@nih.gov
  • Issuing Office: Treatment, Biology, and Sciences Section
  • Contracting Officer:
    Richard L. Hartmann
    Phone: 301-496-8620
    Email: rh75f@nih.gov
  • Set-Aside: No

NCI RFA: Mouse Models of Human Cancers Consortium: U01: RFA: CA-04-002

  • Release Date: October 10, 2002
  • Application Receipt Date: March 19, 2003
  • Expiration Date: N/A

The NCI invites new and competing renewal cooperative agreement (U01) and NIH intramural applications from groups of investigators to continue the Mouse Models of Human Cancers Consortium (MMHCC). The scientific scope of this integrative human/mouse cancer research program may be expanded through incorporation of individuals or groups with additional new perspectives and expertise, such as chemistry, computational and mathematical modeling, and systems biology, to create trans-disciplinary approaches to the design, analysis, and applications of mouse cancer models.

  • Letter of Intent Receipt Date(s): February 19, 2003

See full description in NIH Guide: RFA: CA-04-002

PAR-03-005: Exploratory/Developmental Grants for Quick-Trials for Novel Cancer Therapies: (R21)

  • Release Date: October 07, 2002
  • Application Receipt Date: December 9, 2002, April 9, 2002, August 11, 2003, December 9, 2003, April 9, 2004, August 9, 2004
  • Contacts:
    Keyvan Farahani, Ph.D.
    Email: farahank@mail.nih.gov
    Phone: 301-451-2651

This PA is intended to provide investigators with rapid access to support for pilot, Phase I, and Phase II cancer clinical trials as well as patient monitoring and laboratory studies. The focus of this QUICK-TRIAL PA is on translational research in new agent or device development to ensure the timely exploitation of new cancer therapeutic. This PA is aimed at providing a new approach in the grant application process by offering a rapid turnaround from application submission to funding. Features of this initiative include a modular grant application and award process, inclusion of the clinical protocol within the grant application, and accelerated peer review with the goal of issuing new awards within six months of application receipt. In addition, QUICK-TRIAL applications do not require extensive preliminary data in the grant application and support exploratory translational and clinical research studies involving cancer prevention, chemotherapy and rapid development and application of novel clinical cancer therapies including image guided therapeutic procedures. Investigators may apply for a maximum of two years of funding support using the exploratory or developmental (R21) grant mechanism for up to $250,000 direct costs per year.

See full description in NIH Guide: PAR-03-005

BAA: N01-CO-27031-16 Novel Technologies for Noninvasive Detection, Diagnosis and Treatment of Cancer

  • Release Date: December 04, 2001
  • Application Receipt Date: February 6, 2002
  • Contacts:
    Annmarie Keane
    Phone: 301-496-8620
  • Issuing Office: Treatment, Biology, and Sciences Section
  • Contracting Officer:
    Richard L. Hartmann
    301-496-8620
  • Set-Aside: No

NCI PA: Innovative Technologies for the Molecular Analysis of Cancer: Phase Innovation Award (R21/R33)/ SBIR/STTR (PAR-01-105): Reissue

  • Release Date: May 31, 2001
  • Application Receipt Date: See Below
  • Expiration Date: N/A
  • Contacts:
    Barbara Y. Croft, Ph.D.
    Email: bc129b@nih.gov
    Phone: 301-496-9531

Development of molecular analysis tools to expand our understanding of the biological basis of cancers. The scope includes application of high-resolution imaging at the cellular or molecular scales, tissue samples, pre-clinical models, or clinical investigations as an important extension of molecular analysis methods.

  • Fast-track process
  • No dollar cap for R33
  • Program approval for over $500K
  • Not to exceed $100,000
  • Letter of Intent: June 15, 2001; October 17, 2001; February 14, 2002; June 10, 2002; October 18, 2002; February 14, 2003; and June 16, 2001
  • Application Receipt Date(s): July 20, 2001; November 21, 2001; March 21, 2002; July 22, 2002; November 22, 2002; March 21, 2003; and July 21, 2003
  • Funded Projects (TBA)

See full description in NIH Guide: PAR-01-105

NCI PA: Applications of Innovative Technologies for the Molecular Analysis of Cancer: Phased Technology Application Award (R21/33)/SBIR/STTR (PAR-01-107): Reissue

  • Release Date: May 31, 2001
  • Application Receipt Date: See below
  • Expiration Date: N/A
  • Contacts:
    Barbara Y. Croft, Ph.D.
    Email: bc129b@nih.gov
    Phone: 301-496-9531

To evaluate the utility and pilot the application of molecular analysis technologies in studies relevant to cancer research. Molecular analysis technologies of interest include those that are entirely novel, or emerging but not currently in broad scale use, or technologies currently in use for one application or set of applications, that are being evaluated for utility for alternative applications.

  • Fast-track process
  • No dollar cap for R33
  • Program approval for over $500K
  • Not to exceed $100,000
  • Letter of Intent: June 15, 2001; October 17, 2001; February 14, 2002; June 10, 2002; October 18, 2002; February 14, 2003; and June 16, 2003
  • Application Receipt Date(s): July 20, 2001; November 21, 2001; March 21, 2002; July 22, 2002; November 22, 2002; March 21, 2003; and July 21, 2003
  • Funded Projects (TBA)

See full description in NIH Guide: PAR-01-107

NIH OD-00-016: Nanoscience and Nanotechnology Grant Applications

  • Release Date: January 20, 2000
  • Application Receipt Date: N/A
  • Expiration Date: N/A

See full description in NIH Guide: NIH OD-00-016

NCRR Shared Instrumentation Grant

  • Release Date: December 15, 1999
  • Application Receipt Date: March 17, 2000
  • Expiration Date: N/A

See full description in NIH Guide: NCRR Shared Instrumentation Grant

NLM Visible Human Project Image Processing Tools

  • Release Date: April 01, 1999
  • Application Receipt Date: May 28, 1999
  • Expiration Date: N/A

The National Library of Medicine (NLM) is seeking competitive proposals to develop an application programmer interface (API) and first implementation of a Segmentation and Registration Toolkit (SRT). The resulting system should be suitable for computer assisted exploration of the NLM Visible Human Project (VHP).

  • Awards September 30, 1999

See full description in NIH Guide: NLM-99-103/DJH

NIH PA-98-092: Shared Resources for Scientists Outside NCI Cancer Centers

  • Release Date: July 23, 1998
  • Application Receipt Date: Nov 1998
  • Expiration Date: N/A

Objective of the program is to provide groups of six or more NCI (R01 or P01) funded investigators (non NCI center based) with additional shared resource support.

See full description in NIH Guide: NIH PA-98-092

NIH PA-98-094: Cerebral Radiobiology and Neuro-imaging of Brain Tumors

  • Release Date: July 01, 1998
  • Application Receipt Date: Regular submission times
  • Expiration Date: N/A

NIND and NCI invite applications to support research that will increase our knowledge of the genetic, molecular, cellular and physiological mechanisms of radiation-induced cell injury and recovery; i.e. for the central nervous system (CNS).

  • Announced July 1998
  • R01 or P01 Grants
  • Regular submission times

See full description in NIH Guide:NIH PA-98-094

PA-09-081: PHS 2009-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])

  • Release Date: January 01, 1980

To see announcement: http://grants.nih.gov/grants/guide/pa-files/PA-09-081.htmll

PA-09-080: PHS 2009-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])

  • Release Date: January 01, 1980

To view the announcment, see: http://grants.nih.gov/grants/guide/pa-files/PA-09-080.html